Reviewing Unicycive Therapeutics (NASDAQ:UNCY) and ARS Pharmaceuticals (NASDAQ:SPRY)

Unicycive Therapeutics (NASDAQ:UNCY) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Valuation and Earnings

This table compares Unicycive Therapeutics and ARS Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	317.26	-$26.56 million	($2.21)	-3.66
ARS Pharmaceuticals	$84.28 million	9.36	-$171.30 million	($2.01)	-3.95

Unicycive Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Unicycive Therapeutics and ARS Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Volatility and Risk

Unicycive Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Unicycive Therapeutics and ARS Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1	0	5	0	2.67
ARS Pharmaceuticals	1	1	3	0	2.40

Unicycive Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 197.03%. ARS Pharmaceuticals has a consensus price target of $28.25, suggesting a potential upside of 255.79%. Given ARS Pharmaceuticals’ higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Unicycive Therapeutics.

Summary

Unicycive Therapeutics beats ARS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.